<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278521</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001835</org_study_id>
    <nct_id>NCT04278521</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Transcranial Magnetic Stimulation</brief_title>
  <official_title>Mechanism of Action of Transcranial Magnetic Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational neuroimaging study assessing the effects of TMS on the brains of
      patients with unipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study
      patients with unipolar depression receiving TMS. Patients will be scanned before and after a
      full course of TMS and clinical measures for depression severity and memory will be obtained
      at the same times.The project has the following aims and hypothesis: (1) to determine the
      therapeutic antidepressant mechanism of action of TMS at the circuit level (2) to study the
      use of fcMRI as a state biomarker for depression (3) to study the use of fcMRI as a predictor
      of response for depression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Functional Connectivity of Key Nodes in Depression</measure>
    <time_frame>Through Treatment Completion, Average of 6 Weeks</time_frame>
    <description>Measured by Magnetic Resonance Imaging</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Unipolar Depression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients diagnosed with unipolar depression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.</description>
    <arm_group_label>Unipolar Depression</arm_group_label>
    <other_name>TMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between the ages of 18-80

          2. DSM-IV diagnosis of Depressive Episode

          3. Patients requiring TMS treatment as part of their psychiatric care

        Exclusion Criteria:

          1. Comorbid DSM-IV primary diagnoses of schizoaffective disorder, schizophrenia or
             dementia.

          2. Substance use disorder (abuse or dependence) with active use within the last 3 months

          3. Severe or unstable medical illness.

          4. MRI contraindications as determined by MGH department of radiology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Funes, MS</last_name>
    <phone>6177248780</phone>
    <email>cjfunes@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <phone>6177265348</phone>
    <email>jcamprodon@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Funes, MS</last_name>
      <phone>617-724-8780</phone>
      <email>cjfunes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joan A Camprodon, MD MPH PhD</investigator_full_name>
    <investigator_title>Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation</investigator_title>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

